Symptoms and General Pathology

All Conditions

Infections

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Facies

Warts

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

Dermatologic Agents

All Drugs and Chemicals

Isotretinoin

One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.

One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.

One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.

Isotretinoin capsules

María Guadalupe Olguín-García, M.D., MSc.

Martha Alejandra Morales-Sánchez, M.D., MSc.

María Guadalupe Olguín-García, M.D.,MSc.

Randomized clinical trial to compare the efficacy of different doses of oral isotretinoin 10 mg/day, 20 mg/day and 30 mg/day during 12 weeks for the treatment of facial recalcitrant flat warts. The primary endpoint will be the proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial.

The investigators will recruit 162 participants with facial recalcitrant flat warts and randomize to the following three arms of intervention: Arm 1: nne capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks; Arm 2: one capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks; and Arm 3: one capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks. The primary endpoints will be the proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial; and the incidence of side effects related to oral isotretinoin treatment among the 3 arms of treatment.

All the interventions will be similar in appearance and all the participants will take the same quantity of capsules.

Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts

Efficacy and Safety of Oral Isotretinoin 10 mg, 20 mg and 30 mg for the Treatment of Facial Recalcitrant Flat Warts at Centro Dermatológico "Dr. Ladislao de la Pascua": Randomized Double-blinded Clinical Trial of Three Arms

Proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial.

Proportion of participants that developed a serious side effect in the three arms during the clinical trial.

Difference in the Dermatology Life Quality Index score at the end of the study, comparing with the basal score. The minimum score is 0 points and the maximum 30 points. A score higher than 10 points means that the patient's life is severely affected by melasma.

Percentage of taken-doses of oral isotretinoin during the 12 weeks of the study.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts	NCT04290572	Flat Wart	Isotretinoin ca...	18 Years - 40 Years	Centro Dermatológico Dr. Ladislao de la Pascua
Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts	NCT04290572	Flat Wart	Isotretinoin ca...	18 Years - 40 Years	Centro Dermatológico Dr. Ladislao de la Pascua
Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts	NCT04290572	Flat Wart	Isotretinoin ca...	18 Years - 40 Years	Centro Dermatológico Dr. Ladislao de la Pascua

Spots Global Cancer Trial Database for facial warts

Every month we try and update this database with for facial warts cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.